Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7181116 | 0.91 | MMP8 (0.50) | KMT2AMMP8L3MBTL1MEN1SMN1; SMN2 | |
| SCHEMBL7181823 | 0.88 | L3MBTL1 (0.37) | KMT2AMMP8L3MBTL1MEN1ALDH1A1 | |
| SCHEMBL7177876 | 0.88 | KMT2A (0.46) | KMT2AMMP8L3MBTL1MEN1ALDH1A1 | |
| SCHEMBL7180641 | 0.87 | L3MBTL1 (0.36) | KMT2AMMP8L3MBTL1ALDH1A1LMNA | |
| SCHEMBL7187385 | 0.85 | MMP8 (0.41) | MMP8L3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7174854 | 0.85 | TSHR (0.40) | MMP8L3MBTL1ALDH1A1PTGS1PTGS2 | |
| SCHEMBL7183688 | 0.85 | ALDH1A1 (0.39) | KMT2AMMP8L3MBTL1ALDH1A1LMNA | |
| SCHEMBL7186423 | 0.85 | L3MBTL1 (0.49) | KMT2AMMP8L3MBTL1MEN1ALDH1A1 | |
| SCHEMBL7187443 | 0.85 | KMT2A (0.34) | KMT2AMMP8L3MBTL1MEN1ALDH1A1 | |
| SCHEMBL27499986 | 0.83 | KMT2A (0.47) | KMT2AMMP8L3MBTL1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | KMT2A 1586/4885MMP8 4404/4885L3MBTL1 302/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | KMT2A 956/4885MMP8 4586/4885L3MBTL1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.